AC
PBYI icon

Ascend Capital’s Puma Biotechnology PBYI Stock Holding History

Ascend Capital’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-130,971
Closed -$12.9M – 259
2017
Q4 		$12.9M Sell
130,971
-585,746
-82% -$65.5M 0.49% 65
2017
Q3 		$85.8M Buy
716,717
+656,662
+1,093% +$61.1M 3.24% 2
2017
Q2 		$5.25M Buy
+60,055
New +$3.36M 0.24% 105

Other funds holding PBYI

Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Ascend Capital's PBYI Position: Q1 2018 in Review

Ascend Capital sold out of Puma Biotechnology (PBYI) in Q1 2018, closing a stake of 130,971 shares — an estimated $12.9M sold.

Ascend Capital first reported a position in PBYI in Q2 2017 and held it in 3 quarters. The position peaked at $85.8M in Q3 2017. 178 funds tracked by Wall St. Rank hold PBYI as of Q1 2018.

  • Ascend Capital reported no remaining Puma Biotechnology position as of Q1 2018 after selling out during the quarter.
  • Ascend Capital sold 130,971 Puma Biotechnology shares in Q1 2018, an estimated $12.9M.
  • Ascend Capital first reported a position in Puma Biotechnology in Q2 2017 and held it in 3 quarters.
  • Ascend Capital's Puma Biotechnology position peaked at $85.8M in Q3 2017.
  • 178 funds tracked by Wall St. Rank held Puma Biotechnology as of Q1 2018.

Based on Ascend Capital's 13F filing for Q1 2018, filed 14 May 2018.